As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.
23 Analysts have issued a Merus N.V. forecast:
23 Analysts have issued a Merus N.V. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 57 57 |
58%
58%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -369 -369 |
61%
61%
|
|
| EBIT (Operating Income) EBIT | -371 -371 |
61%
61%
|
|
| Net Profit | -381 -381 |
56%
56%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
| Head office | Netherlands |
| CEO | Bill Lundberg |
| Employees | 291 |
| Founded | 2003 |
| Website | merus.nl |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


